Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II umbrella neoadjuvant targeted/immunotherapy plus chemotherapy in stage III NSCLC
ChiCTR2000036594Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib, crizotinib and durvalumab in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Pathological remission rate, Objective response rate and 1 more. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000036594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036594.